Results 1 to 10 of about 3,819 (202)

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran [PDF]

Scientific Reports
Dabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than ...
Jong-Min Kim, Young Yoon Bang, Kyoung-Ah Kim, Jin-Woo Park, Ji-Young Park   +4 more
doaj   +2 more sources

Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab [PDF]

Neurotrauma Reports, 2023
Use of anticoagulants is increasing with the aging of societies. The safe first-line drug is likely to be a direct oral anticoagulant (DOAC), but outcomes of treatment of traumatic brain injury (TBI) with anticoagulants are uncertain.
Eiichi Suehiro, Hideyuki Ishihara, Yohei Kogeichi, Tsunenori Ozawa, Koichi Haraguchi, Masaru Honda, Yumie Honda, Makoto Inaba, Ryusuke Kabeya, Naoaki Kanda, Kenta Koketsu, Nobukuni Murakami, Hidetoshi Nakamoto, Kotaro Oshio, Kuniyasu Saigusa, Takashi Shuto, Shuichi Sugiyama, Kenji Suzuyama, Tsuguaki Terashima, Mitsuharu Tsuura, Mitsutoshi Nakada, Hitoshi Kobata, Toshio Higashi, Nobuyuki Sakai, Michiyasu Suzuki   +24 more
doaj   +2 more sources

Idarucizumab Reversal in Subdural Hemorrhage: A Single-Center Experience [PDF]

Life
Prompt reversal of anticoagulation in the elderly population with subdural hematoma (SDH) is critical to reduce morbidity and facilitate timely surgical intervention. In patients receiving dabigatran, idarucizumab provides rapid anticoagulation reversal.
Anita Mrvar Brečko, Monika Simerl Jožef, Ana Trebše, Matija Zupan, Tomaž Velnar, Senta Frol   +5 more
doaj   +2 more sources

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

Cardiology and Therapy, 2020
Introduction Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016.
Hidesaku Asakura, Teiichi Yamane, Daisuke Nakayama   +2 more
exaly   +2 more sources

Idarucizumab in dabigatran-treated patients with acute stroke: a review and clinical update [PDF]

Frontiers in Neurology
Idarucizumab is an antibody fragment specific for the immediate reversal of dabigatran anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients suffering from life-threatening or uncontrolled bleeding and those in need
Senta Frol, Senta Frol, Janja Pretnar Oblak, Janja Pretnar Oblak, Mišo Šabovič, Mišo Šabovič, George Ntaios, Pawel Kermer, Pawel Kermer   +8 more
doaj   +2 more sources

Bleeding Risk of Anticoagulation Reversal Strategies Before Heart Transplantation: A Retrospective Comparative Cohort Study [PDF]

Journal of Cardiovascular Development and Disease
Heart transplantation (HT) poses high bleeding risks, especially for patients on anticoagulation. This study evaluates the use of idarucizumab for dabigatran (DBG) reversal compared to vitamin K antagonist (VKA) strategies in HT. A retrospective analysis
Antonio Prieto-Romero, Sara Ibañez-García, Xandra García-González, Javier Castrodeza, Beatriz Torroba-Sanz, Carlos Ortiz-Bautista, Cristina Pascual-Izquierdo, José María Barrio-Gutiérrez, Ángel González-Pinto, Ana Herranz-Alonso, María Sanjurjo-Sáez   +10 more
doaj   +2 more sources

Reversal of dabigatran and apixaban-induced coagulopathy using idarucizumab, fibrinogen, and prothrombin complex concentrate: A case report [PDF]

Heliyon
This case report examines the combined use of fibrinogen concentrate, four-factor prothrombin complex concentrate (PCC), and idarucizumab, a specific antidote for dabigatran, to reverse the anticoagulant effects of dabigatran and apixaban-induced ...
Elia Morando, Lorenzo Losso, Massimo Carollo, Ilaria Costantini, Matilde Bacchion, Lucia Drezza, Giorgio Ricci   +6 more
doaj   +2 more sources

Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile [PDF]

Cost Effectiveness and Resource Allocation
Background Atrial fibrillation (AF) is the most common sustained arrhythmia in adults, associated with significant morbidity, mortality, and economic burden due to thromboembolic events.
Tomás Abbot, Nicolás Armijo, Luis Rojas Orellana, Andrés Giglio Jiménez, Carlos Balmaceda, Manuel Espinoza   +5 more
doaj   +2 more sources

Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report [PDF]

International Journal of Emergency Medicine
Dabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli, Olivier Pantet, Julien Castioni, Nima Vakilzadeh, Lorenzo Alberio, Olivier Hugli   +5 more
doaj   +2 more sources

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran

Drug Design, Development and Therapy, 2016
Pierre Sié Hematology Laboratory, Academic Hospital of Toulouse, Hospital Rangueil, Toulouse, France Abstract: Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous ...
Pierre M Sié
exaly   +2 more sources